-
ESMO-MCBS Evaluation and French Derogatory Access Decision: Is There a Correlation?
Sep 9, 2025, 16:22 PM -
Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024
Sep 9, 2025, 16:22 PM -
Changes in Physical Activity of Pediatric Patients Treated With Damoctocog Alfa Pegol During the Alfa-PROTECT Clinical Trial
Sep 9, 2025, 16:22 PM -
Lessons From the NHS AI Awards: Experience of Evaluating AI Tools in Real-World Environments
Sep 9, 2025, 16:22 PM -
Insights on Progress Toward Patient-Centered HTA Through Evaluation of PRO Integration, Value Disconnects, and Policy Change in the EU5
Sep 9, 2025, 16:22 PM -
Which Country Is Currently Reporting the Lowest Global Prices for Semaglutide, and Why?
Sep 9, 2025, 16:22 PM -
A Comparative Analysis of the Nordic Market Access Pathways for Medical Devices
Sep 9, 2025, 16:22 PM -
Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies
Sep 9, 2025, 16:22 PM -
Informing Health System Reform Through Patient Perspectives: Saudi Arabia’s OECD Paris Survey Results
Sep 9, 2025, 16:22 PM -
Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective
Sep 9, 2025, 16:22 PM -
Quality of Life in Patients With Severe Hemophilia A With Inhibitors Treated With Emicizumab in Mexico
Sep 9, 2025, 16:22 PM -
Economic Burden in Metastatic Triple-Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR)
Sep 9, 2025, 16:22 PM -
Treatments for Children With Newly Diagnosed Medulloblastoma: A Systematic Review Of Randomized Controlled Trials
Sep 9, 2025, 16:22 PM -
Modeling Treatment-Free Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukemia: Assumptions, Methodology, and Projections
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in Spain
Sep 9, 2025, 16:22 PM -
Healthcare Costs in People With Type 2 Diabetes Remaining on or Escalating From Basal-Supported Oral Therapy: A 5-Year German Statutory Health Insurance Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Out of Sight, Out of Mind? A Simulation Study Assessing the Use of Quantitative Bias Analysis for Outcome Misclassification in Single-Arm Trials With External Control Comparisons
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Generalizing the Lp(a) Dosing in Secondary Prevention in a Population of French Patients With Cardiovascular Disease
Sep 9, 2025, 16:22 PM -
Quantification of Life-Cycle Value Using Early Modeling to Support RD and Strategy Decisions: A Case Study of a Polymeric Heart Valve
Sep 9, 2025, 16:22 PM
